Summary of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings on May 17, 2018

May 17, 2018 - By Vernon Prom

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Corporate Logo

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Coverage

A total of 3 analysts rate Fresenius Medical Care (NYSE:FMS) as follows: 2 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 67% are bullish. (NYSE:FMS) has 3 ratings reports on May 17, 2018 according to StockzIntelligence. On Monday, December 11 the firm earned “Equal-Weight” rating by Morgan Stanley. On Wednesday, December 20 the firm earned “Buy” rating by SunTrust. On Tuesday, April 24 the firm has “Buy” rating by Deutsche Bank given. Listed here are Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PTs and latest ratings.

24/04/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
20/12/2017 Broker: SunTrust Rating: Buy New Target: $62.0 Maintain
11/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade

The stock increased 1.92% or $0.975 during the last trading session, reaching $51.625.Fresenius Medical Care AG & Co. KGaA has volume of 4,184 shares. Since May 17, 2017 FMS has risen 18.90% and is uptrending. The stock outperformed the S&P 500 by 7.35%.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services.The company has $31.73 billion market cap. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.20.63 is the P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

A couple more Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) news were released by: Nasdaq.com which released on April 27, 2018 “Why Akorn, Inc.’s Stock Is Up Big Today”, also Nasdaq.com on April 23, 2018 released “Why Chicago Bridge & Iron, Akorn, and Flotek Industries Slumped Today”, the next Seekingalpha.com is “Fresenius Medical Care AG & Co. KGaA (FMS) Q1 2018 Results – Earnings Call Transcript” on May 03, 2018. Benzinga.com has article titled “24 Stocks Moving In Monday’s Pre-Market Session”.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.